Indazole-derivatives as factor Xa inhibitors

Details for Australian Patent Application No. 2004238499 (hide)

Owner Aventis Pharma Deutschland GmbH

Inventors Bauer, Armin; Laux, Volker; Nazare, Marc; Wehner, Volkmar; Urmann, Matthias; Matter, Hans

Agent Watermark

Pub. Number AU-A-2004238499

PCT Pub. Number WO2004/101556

Priority 03011303.9 19.05.03 EP

Filing date 5 May 2004

Wipo publication date 25 November 2004

International Classifications

C07D 413/14 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 031/416 - condensed with carbocyclic ring systems, e.g. indazole

C07D 401/12 Heterocyclic compounds containing two or more hetero rings

A61P 007/02 Drugs for disorders of the blood or the extracellular fluid

C07D 413/04 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 401/14 Heterocyclic compounds containing two or more hetero rings

Event Publications

8 December 2005 PCT application entered the National Phase

  PCT publication WO2004/101556 Priority application(s): WO2004/101556

5 November 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004238500-Azaindole-derivatives as factor Xa inhibitors

2004238498-Triazole-derivatives as factor Xa inhibitors